BACKGROUND: In this report, the authors describe their collective experience with melphalan-based autotransplants since the inception of their program at the University of Arkansas for Medical Sciences in 1989. METHODS: The authors evaluated the clinical outcomes of 3077 successive patients with multiple myeloma (MM) who underwent at least 1 melphalan-based autotransplantation at the University of Arkansas. Of these, 1078 patients were enrolled on front-line Total Therapy (TT) protocols (TT-P) TT1, TT2, and TT3; 1104 patients were entered on protocols for newly diagnosed or previously treated patients (non-TT-P); and 895 patients were treated off protocol (non-P). RESULTS: The 10-year overall survival (OS) rates after first transplantation were 41%, 19%, and 11% (P< .001) for the TT-P, non-TT-P, and non-P groups, respectively. In the TT-P group, the median OS was 72 months on TT1, was not reached at >or= 7 years on TT2, and was 88% at 2 years on TT3. Among 2683 patients with complete baseline data, absence of hypodiploidy/chromosome 13 deletion, beta-(2)-microglobulin <3.0 mg/L, C-reactive protein <6 mg/L, albumin >or= 3.0 g/dL, and platelet count >or= 100,000/microL all were associated independently with superior OS (P< .001), event-free survival (P< .001), and duration of complete remission (P< .001). CONCLUSIONS: The results from this large, single-institution experience demonstrated that >10-year OS was accomplished in >40% of all patients enrolled on TT-P, whereas such success was observed in only 15% of the remaining patients (including 25% in the presence of all 5 good-risk features). Superior outcomes with protocol-based, primary transplant regimens such as TT-P draw attention to the importance of applying the best available therapies upfront.
BACKGROUND: In this report, the authors describe their collective experience with melphalan-based autotransplants since the inception of their program at the University of Arkansas for Medical Sciences in 1989. METHODS: The authors evaluated the clinical outcomes of 3077 successive patients with multiple myeloma (MM) who underwent at least 1 melphalan-based autotransplantation at the University of Arkansas. Of these, 1078 patients were enrolled on front-line Total Therapy (TT) protocols (TT-P) TT1, TT2, and TT3; 1104 patients were entered on protocols for newly diagnosed or previously treated patients (non-TT-P); and 895 patients were treated off protocol (non-P). RESULTS: The 10-year overall survival (OS) rates after first transplantation were 41%, 19%, and 11% (P< .001) for the TT-P, non-TT-P, and non-P groups, respectively. In the TT-P group, the median OS was 72 months on TT1, was not reached at >or= 7 years on TT2, and was 88% at 2 years on TT3. Among 2683 patients with complete baseline data, absence of hypodiploidy/chromosome 13 deletion, beta-(2)-microglobulin <3.0 mg/L, C-reactive protein <6 mg/L, albumin >or= 3.0 g/dL, and platelet count >or= 100,000/microL all were associated independently with superior OS (P< .001), event-free survival (P< .001), and duration of complete remission (P< .001). CONCLUSIONS: The results from this large, single-institution experience demonstrated that >10-year OS was accomplished in >40% of all patients enrolled on TT-P, whereas such success was observed in only 15% of the remaining patients (including 25% in the presence of all 5 good-risk features). Superior outcomes with protocol-based, primary transplant regimens such as TT-P draw attention to the importance of applying the best available therapies upfront.
Authors: R Desikan; B Barlogie; J Sawyer; D Ayers; G Tricot; A Badros; M Zangari; N C Munshi; E Anaissie; D Spoon; D Siegel; S Jagannath; D Vesole; J Epstein; J Shaughnessy; A Fassas; S Lim; P Roberson; J Crowley Journal: Blood Date: 2000-06-15 Impact factor: 22.113
Authors: J Anthony Child; Gareth J Morgan; Faith E Davies; Roger G Owen; Susan E Bell; Kim Hawkins; Julia Brown; Mark T Drayson; Peter J Selby Journal: N Engl J Med Date: 2003-05-08 Impact factor: 91.245
Authors: E Terpos; E Kastritis; M Roussou; D Heath; D Christoulas; N Anagnostopoulos; E Eleftherakis-Papaiakovou; K Tsionos; P Croucher; M A Dimopoulos Journal: Leukemia Date: 2008-09-04 Impact factor: 11.528
Authors: V Arzoumanian; A Hoering; J Sawyer; F van Rhee; C Bailey; J Gurley; J D Shaughnessy; E Anaissie; J Crowley; B Barlogie Journal: Leukemia Date: 2008-01-17 Impact factor: 11.528
Authors: George Somlo; Ricardo Spielberger; Paul Frankel; Chatchada Karanes; Amrita Krishnan; Pablo Parker; Leslie Popplewell; Firoozeh Sahebi; Neil Kogut; David Snyder; An Liu; Timothy Schultheiss; Stephen Forman; Jeffrey Y C Wong Journal: Clin Cancer Res Date: 2010-11-03 Impact factor: 12.531
Authors: Laura Rosiñol; Ramón García-Sanz; Juan José Lahuerta; Miguel Hernández-García; Miquel Granell; Javier de la Rubia; Albert Oriol; Belén Hernández-Ruiz; Consuelo Rayón; Isabel Navarro; Juan Carlos García-Ruiz; Joan Besalduch; Santiago Gardella; Javier López Jiménez; Joaquín Díaz-Mediavilla; Adrián Alegre; Jesús San Miguel; Joan Bladé Journal: Haematologica Date: 2011-11-04 Impact factor: 9.941
Authors: R Chakraborty; E Muchtar; S K Kumar; F K Buadi; D Dingli; A Dispenzieri; S R Hayman; W J Hogan; P Kapoor; M Q Lacy; N Leung; M A Gertz Journal: Bone Marrow Transplant Date: 2017-11-13 Impact factor: 5.483
Authors: Paul G Richardson; Ashraf Z Badros; Sundar Jagannath; Stefano Tarantolo; Jeffrey L Wolf; Maher Albitar; David Berman; Marianne Messina; Kenneth C Anderson Journal: Br J Haematol Date: 2010-07-07 Impact factor: 6.998
Authors: Bart Barlogie; Elias Anaissie; Frits van Rhee; Mauricio Pineda-Roman; Maurizio Zangari; John Shaughnessy; Joshua Epstein; John Crowley Journal: Best Pract Res Clin Haematol Date: 2007-12 Impact factor: 3.020